{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:12:14Z","timestamp":1789391534374,"version":"build-2803163510"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2012,3,30]],"date-time":"2012-03-30T00:00:00Z","timestamp":1333065600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0034134","type":"journal-article","created":{"date-parts":[[2012,3,30]],"date-time":"2012-03-30T21:11:23Z","timestamp":1333141883000},"page":"e34134","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial"],"prefix":"10.1371","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct00080106","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jonathan Z.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanson J.","family":"Brumme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Lederman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zabrina L.","family":"Brumme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Spritzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Carrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Medvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Schooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Kuritzkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the AIDS Clinical Trials Group A5197 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,3,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1165706","article-title":"The challenge of finding a cure for HIV infection.","volume":"323","author":"DD Richman","year":"2009","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","article-title":"Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.","volume":"304","author":"MA Thompson","year":"2010","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1089\/aid.2010.0087","article-title":"HIV cure: controversy, consensus, and a consortium.","volume":"26","author":"R Johnston","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jama.2010.957","article-title":"Controlling and ultimately ending the HIV\/AIDS pandemic: a feasible goal.","volume":"304","author":"GK Folkers","year":"2010","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/COH.0b013e3280119264","article-title":"Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption.","volume":"2","author":"MM Lederman","year":"2007","journal-title":"Curr Opin HIV AIDS"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1086\/655468","article-title":"AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.","volume":"202","author":"RT Schooley","year":"2010","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/infdis\/jiq143","article-title":"Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.","volume":"203","author":"JZ Li","year":"2011","journal-title":"J Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1310\/hct0905-324","article-title":"Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.","volume":"9","author":"M van den Berg-Wolf","year":"2008","journal-title":"HIV Clin Trials"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/QAD.0b013e3283333639","article-title":"Outcomes after virologic failure of first-line ART in South Africa.","volume":"24","author":"RA Murphy","year":"2010","journal-title":"AIDS"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1473-3099(10)70313-3","article-title":"First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2\/3 trial.","volume":"11","author":"A Babiker","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1086\/382895","article-title":"No evidence of an association between transient HIV viremia (\u201cBlips\u201d) and lower adherence to the antiretroviral medication regimen.","volume":"189","author":"LG Miller","year":"2004","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1086\/496985","article-title":"Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.","volume":"41","author":"S Sungkanuparph","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1056\/NEJM200105313442203","article-title":"Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.","volume":"344","author":"X Gao","year":"2001","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1089\/aid.2006.22.1081","article-title":"A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects.","volume":"22","author":"TW Tobery","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/107999003322226023","article-title":"Intracellular staining for HIV-specific IFN-gamma production: statistical analyses establish reproducibility and criteria for distinguishing positive responses.","volume":"23","author":"WL Trigona","year":"2003","journal-title":"J Interferon Cytokine Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e6687","DOI":"10.1371\/journal.pone.0006687","article-title":"HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.","volume":"4","author":"ZL Brumme","year":"2009","journal-title":"PLoS ONE"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002030-200201040-00004","article-title":"Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen.","volume":"16","author":"V Le Moing","year":"2002","journal-title":"AIDS"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/00002030-200007280-00003","article-title":"Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.","volume":"14","author":"JP Ioannidis","year":"2000","journal-title":"AIDS"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/archinte.163.10.1220","article-title":"A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.","volume":"163","author":"C Fagard","year":"2003","journal-title":"Arch Intern Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1097\/00002030-200312050-00005","article-title":"Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.","volume":"17","author":"M Altfeld","year":"2003","journal-title":"Aids"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nature03113","article-title":"Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.","volume":"432","author":"P Kiepiela","year":"2004","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1371\/journal.pmed.0030403","article-title":"HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1.","volume":"3","author":"M Altfeld","year":"2006","journal-title":"PLoS Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1128\/JVI.02689-06","article-title":"Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes.","volume":"81","author":"I Honeyborne","year":"2007","journal-title":"J Virol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1126\/science.1195271","article-title":"The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.","volume":"330","author":"F Pereyra","year":"2010","journal-title":"Science"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/infdis\/jiq114","article-title":"An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study).","volume":"203","author":"DW Fitzgerald","year":"2011","journal-title":"J Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"12638","DOI":"10.1128\/JVI.78.22.12638-12646.2004","article-title":"Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels.","volume":"78","author":"E Boritz","year":"2004","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e5013","DOI":"10.1371\/journal.pone.0005013","article-title":"Immunodominant HIV-1 Cd4+ T cell epitopes in chronic untreated clade C HIV-1 infection.","volume":"4","author":"D Ramduth","year":"2009","journal-title":"PLoS One"},{"key":"ref28","article-title":"Gag-specific CD4+ T-cell responses are associated with virological control of paediatric HIV-1 infection.","author":"A Prendergast","year":"2011","journal-title":"AIDS"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/QAD.0b013e3282fdce94","article-title":"Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).","volume":"22","author":"B Autran","year":"2008","journal-title":"AIDS"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/QAD.0b013e328340fe55","article-title":"Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine.","volume":"25","author":"L Papagno","year":"2011","journal-title":"AIDS"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.4049\/jimmunol.0803771","article-title":"PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention.","volume":"182","author":"DE Kaufmann","year":"2009","journal-title":"J Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.","volume":"443","author":"CL Day","year":"2006","journal-title":"Nature"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/ni1515","article-title":"Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.","volume":"8","author":"DE Kaufmann","year":"2007","journal-title":"Nat Immunol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1084\/jem.191.11.1987","article-title":"Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule.","volume":"191","author":"JL Riley","year":"2000","journal-title":"J Exp Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0034134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T00:57:36Z","timestamp":1539997056000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0034134"}},"subtitle":[],"editor":[{"given":"Barbara","family":"Ensoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,3,30]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,3,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0034134","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,30]]}}}